Enitotciclib induced downregulation of RNAPol2 mediated transcription
The project investigates the pharmacodynamic (PD) effect of CDK9 inhibition (using Enitociclib, a selective CDK9 inhibitor) in preclinical models and in blood samples from patients (DH-DLBCL [n=10] and MYC+ NHL [n=5]) treated with 30 mg i.v. QW enitociclib.